Table 2. Clinical characteristics of patients with IBD and controls.
| Biopsy samples |
Blood samples |
|||||
|---|---|---|---|---|---|---|
| Con | CD | UC | Con | CD | UC | |
| Numbers of patients | 16 | 38 | 17 | 30 | 179 | 66 |
| Age (y) | 46.1 ± 6.9 | 41.3 ± 16.8 | 34.6 ± 13.3 | 37.2 ± 9.8 | 42.6 ± 11.2 | 38.7 ± 10.3 |
| Gender | ||||||
| Male | 8 | 17 | 7 | 15 | 64 | 44 |
| Female | 8 | 21 | 10 | 15 | 115 | 22 |
| Disease duration (month) | 43.2 ± 17.2 | 49.2 ± 23.5 | 32.5 ± 22.1 | 39.6 ± 20.2 | ||
| Current therapy | ||||||
| 5-aminosalicylates | 32 | 11 | 153 | 51 | ||
| Immunosuppressants | 0 | 0 | 0 | 0 | ||
| Biologics | 0 | 0 | 0 | 0 | ||
| Nutritional therapy | 2 | 0 | 7 | 4 | ||
| Disease extent (UC)* | ||||||
| E1 | 4 | 8 | ||||
| E2 | 7 | 28 | ||||
| E3 | 6 | 30 | ||||
| Disease location (CD)* | ||||||
| L1 | 9 | 37 | ||||
| L2 | 13 | 45 | ||||
| L3 | 16 | 97 | ||||
| L4 | 0 | 0 | ||||
*According to the Montreal classification system.